Well into my third round of B + R chemo treatment yesterday and today - and all seems to be going well! My IVIG Infusions have now caught up with my delayed Chemo treatment - so three session in the Day Care Unit - this week!
After my last Doctor's examination & blood tests he now strongly suspects that I am actually receiving the trial drug Idelalisib (CAL 101.) and not the placebo, due to the effects that can be seen in my body and blood.
Even with these apparently positive responses - I am still maintaining my vigilance on bugs and infection! (Which reminds me to check when the Flu Jab season starts ! )
GOOD NEWS Report
On September 11, 2013, Gilead Sciences Inc. (Gilead) announced that the Company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta for the treatment of indolent non-Hodgkin's lymphoma (iNHL). Gilead also informed that along with this NDA, the Company submitted data that supports the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. The Company further added that it plans to file for regulatory approval of idelalisib in the European Union in Q4 2013
So best wishes to all for a great weekend !